Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815175 · ClinicalTrials.gov registry record · NA
XIENCE 28 USA Study
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 1,605
- Enrollment target
NCT03815175 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,605 participants.
The verdict
NCT03815175, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,605 participants
- Enrollment target
Study Summary
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting Coronary Stent System \[EECSS\], XIENCE Alpine EECSS and XIENCE Sierra EECSS) of coronary drug-eluting stents.
Interventions
- DEVICE XIENCE
- DRUG DAPT (aspirin and/or P2Y12 receptor inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,605 participants |
| Start Date | 2019-02-25 |
| Est. Completion | 2021-02-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815175
The ClinicalTrials.gov registry entry for NCT03815175 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,605 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XIENCE is the first listed.
NCT03815175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03815175 about?
NCT03815175 is a clinical study titled "XIENCE 28 USA Study". The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIE...
What is the current status of trial NCT03815175?
This trial is currently completed. It is a NA study. The enrollment target is 1,605 participants. The study started on 2019-02-25. Estimated completion is 2021-02-04.
What interventions are being tested in trial NCT03815175?
The interventions under investigation include: XIENCE (DEVICE), DAPT (aspirin and/or P2Y12 receptor inhibitor) (DRUG).
Who is sponsoring clinical trial NCT03815175?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.